Literature DB >> 25486950

Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.

Nina Shah1, Katy Rezvani2, Chitra Hosing2, Partow Kebriaei2, William Wierda3, Laurence Cooper4, Elizabeth Shpall2.   

Abstract

Over the past several years there has been considerable progress in the number and breadth of therapeutic options for patients with chronic lymphocytic leukemia. In particular, cumulative experience with stem cell transplant and immunotherapy has made these modalities more available to a broader range of patients. Advances in genetic engineering and ex vivo expansion techniques have sculpted cellular therapy products to optimize the combination of specificity and toxicity. This brief review discusses recent cutting-edge experience with chimeric antigen receptor T cells as well as developing cellular therapy products at the authors' institution.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chimeric antigen receptors; Immunotherapy; NK cells; Stem cell transplant; T cells

Mesh：

Substances：

Year:  2014        PMID： 25486950      PMCID： PMC4844462          DOI： 10.1016/j.clml.2014.06.013

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


  20 in total

1.  Expression of ROR1 in patients with renal cancer--a potential diagnostic marker.

Authors:  Hodjattallah Rabbani; Mahyar Ostadkarampour; Amir Hossein Danesh Manesh; Abbas Basiri; Mahmood Jeddi-Tehrani; Flora Forouzesh
Journal:  Iran Biomed J       Date:  2010-07

2.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Authors:  James N Kochenderfer; Mark E Dudley; Robert O Carpenter; Sadik H Kassim; Jeremy J Rose; William G Telford; Frances T Hakim; David C Halverson; Daniel H Fowler; Nancy M Hardy; Anthony R Mato; Dennis D Hickstein; Juan C Gea-Banacloche; Steven Z Pavletic; Claude Sportes; Irina Maric; Steven A Feldman; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Bipulendu Jena; Michael R Bishop; Ronald E Gress; Steven A Rosenberg
Journal:  Blood       Date:  2013-09-20       Impact factor: 22.113

Review 3.  Use of natural killer cells in hematopoetic stem cell transplantation.

Authors:  J R Passweg; M Stern; U Koehl; L Uharek; A Tichelli
Journal:  Bone Marrow Transplant       Date:  2005-04       Impact factor: 5.483

4.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

Authors:  Bipin N Savani; Katayoun Rezvani; Stephan Mielke; Aldemar Montero; Roger Kurlander; Charles S Carter; Susan Leitman; Elizabeth J Read; Richard Childs; A John Barrett
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

5.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Authors:  Michael Hudecek; Thomas M Schmitt; Sivasubramanian Baskar; Maria Teresa Lupo-Stanghellini; Tetsuya Nishida; Tori N Yamamoto; Marie Bleakley; Cameron J Turtle; Wen-Chung Chang; Harvey A Greisman; Brent Wood; David G Maloney; Michael C Jensen; Christoph Rader; Stanley R Riddell
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

Review 6.  Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation.

Authors:  Loredana Ruggeri; Marusca Capanni; Antonella Mancusi; Elena Urbani; Katia Perruccio; Emanuela Burchielli; Antonella Tosti; Fabiana Topini; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood Cells Mol Dis       Date:  2004 Nov-Dec       Impact factor: 3.039

7.  KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.

Authors:  Katharine C Hsu; Ted Gooley; Mari Malkki; Clara Pinto-Agnello; Bo Dupont; Jean-Denis Bignon; Martin Bornhäuser; Frank Christiansen; Alois Gratwohl; Yasuo Morishima; Machteld Oudshoorn; Olle Ringden; Jon J van Rood; Effie Petersdorf
Journal:  Biol Blood Marrow Transplant       Date:  2006-08       Impact factor: 5.742

8.  Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.

Authors:  M Lioznov; J El-Cheikh; F Hoffmann; Y Hildebrandt; F Ayuk; C Wolschke; D Atanackovic; G Schilling; A Badbaran; U Bacher; B Fehse; A R Zander; D Blaise; M Mohty; N Kröger
Journal:  Bone Marrow Transplant       Date:  2009-07-06       Impact factor: 5.483

9.  Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.

Authors:  Dan Zhu; Laura G Corral; Yuedi W Fleming; Bernd Stein
Journal:  Cancer Immunol Immunother       Date:  2008-04-08       Impact factor: 6.968

10.  Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

Authors:  Nina Shah; Beatriz Martin-Antonio; Hong Yang; Stephanie Ku; Dean A Lee; Laurence J N Cooper; William K Decker; Sufang Li; Simon N Robinson; Takuya Sekine; Simrit Parmar; John Gribben; Michael Wang; Katy Rezvani; Eric Yvon; Amer Najjar; Jared Burks; Indreshpal Kaur; Richard E Champlin; Catherine M Bollard; Elizabeth J Shpall
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240
View more
  2 in total

1.  Matrine increases NKG2D ligand ULBP2 in K562 cells via inhibiting JAK/STAT3 pathway: a potential mechanism underlying the immunotherapy of matrine in leukemia.

Authors:  Xuzhang Lu; Zhichao Zhu; Lijia Jiang; Xiao Sun; Zhuxia Jia; Sixuan Qian; Jianyong Li; Lingdi Ma
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

2.  Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment.

Authors:  Jillian R Gunther; Ahmad R Rahman; Wenli Dong; Zeinab Abou Yehia; Partow Kebriaei; Gabriela Rondon; Chelsea C Pinnix; Sarah A Milgrom; Pamela K Allen; Bouthaina S Dabaja; Grace L Smith
Journal:  Pract Radiat Oncol       Date:  2017-05-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.